Sildenafil Tablet, Film Coated
Product Images NDC 0904-6671

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 0904-6671). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

0de47bba 965a 4039 9237 F10ea6d9f669 00

This is a product description of sildenafil tablets, USP. The tablets come in blister packs of 4 and each tablet contains 1020mg of sildenafil. There is advice to consult a healthcare professional regarding proper usage and safety precautions. There are also instructions to keep the medication out of reach of children and to store it in a tightly sealed container with acid-resistant material. The description also includes a prescription warning and pharmacy information.*

FDA Label Image

2 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 01)

FDA Label Image

1 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 02)

FDA Label Image

7 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 03)

This is a table that shows the drug fold change and corresponding 90% confidence interval (CI) recommendation for interacting drugs with Atorvastatin, Adithromycin, Bosentan, Cimetidine, Mes, Erythromycin, Maslox, Oral Contraceptives, Rioravir, and Saquinavir in terms of AUC and cmax. The study found that adding Sildenafil to Bosentan therapy did not improve exercise capacity based on clinical studies.*

FDA Label Image

8 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 04)

This text appears to be a table that lists different drugs and their potential interactions with the drug Acenocoumarol. The table provides information on the impact of the interaction on INR AUC, Cmax, and fold change with an 80% Cl. Based on the effects, there are recommendations for dose adjustment and co-administration. Some drugs require no dose adjustment and are safe to co-administer, while others are not recommended or require further monitoring. The table also includes some clinical study results on exercise capacity when Sidonati is added to Bosentan therapy.*

FDA Label Image

4 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 05)

FDA Label Image

5 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 06)

This is a clinical trial data that includes the dosage of Placebo and Sildenafil 20 mg TID administered to a group of patients diagnosed with Idiopathic PAH. The data includes the mean PAP, gender, age, and walk distance and its change in 6-minutes before and after administering the medication.*

FDA Label Image

1 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 07)

FDA Label Image

Figure 12 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 08)

The given text is a figure showing the mean change from baseline in the six-minute walk test in meters for a study involving the use of Sildenafil. The data is presented for the ITT population up to week 12. The figure shows a line graph with three treatment groups: Sildenafil 1mg TID, Sildenafil 5mg TID, and Sildenafil 20mg TID. The X-axis shows the weeks of the study, and the Y-axis shows the change from baseline (meters). The figure includes error bars, representing Standard Error, and provides information on the mean change in each treatment at each visit.*

FDA Label Image

9 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 09)

FDA Label Image

9 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 10)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.